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Abstract
Background: The relationship between airway structural changes (remodeling) and airways hyperresponsiveness
(AHR) is unclear. Asthma guidelines suggest treating persistent asthma with inhaled corticosteroids and long acting
b-agonists (LABA). We examined the link between physiological function and structural changes following
treatment fluticasone and salmeterol separately or in combination in a mouse model of allergic asthma.
Methods: BALB/c mice were sensitized to intraperitoneal ovalbumin (OVA) followed by six daily inhalation
exposures. Treatments included 9 daily nebulized administrations of fluticasone alone (6 mg/ml), salmeterol (3 mg/
ml), or the combination fluticasone and salmeterol. Lung impedance was measured following methacholine
inhalation challenge. Airway inflammation, epithelial injury, mucus containing cells, and collagen content were
assessed 48 hours after OVA challenge. Lungs were imaged using micro-CT.
Results and Discussion: Treatment of allergic airways disease with fluticasone alone or in combination with
salmeterol reduced AHR to approximately naüve levels while salmeterol alone increased elastance by 39%
compared to control. Fluticasone alone and fluticasone in combination with salmeterol both reduced inflammation
to near naive levels. Mucin containing cells were also reduced with fluticasone and fluticasone in combination with
salmeterol.
Conclusions: Fluticasone alone and in combination with salmeterol reduces airway inflammation and remodeling,
but salmeterol alone worsens AHR: and these functional changes are consistent with the concomitant changes in
mucus metaplasia.
Background
There is a variety of pathological changes that are thera-
peutic targets in asthma [1]. Principal among these is
periodic or persistent inflammation, which is the cardi-
nal feature of allergic asthma that presumably leads to
the persistent structural changes known as remodeling.
Remodeling includes a spectrum of alterations including
collagen deposition, epithelial thickening, goblet cell
hyperplasia and smooth muscle thickening. The overall
functional consequences of airway remodeling remain
uncertain [2], but the consequences are generally cast as
detrimental. The propensity for the distal airways of
asthmatics to become plugged with mucus is a well-
known hallmark of fatal asthma [3]. Mucus also likely
plays an important role in the distal airway closure that
underlies the AHR of allergically inflamed mice [4-6].
Mitigation of the inflammation induced remodeling may
therefore, be a key goal in asthma treatment.
Clinical guidelines call for asthma treatment with
inhaled corticosteroids (ICS) and long acting b-agonists
(LABA) for moderate and severe persistent asthma [7].
The combination of LABA and ICS is apparently more
effective than simply doubling the dose of ICS [8]; how-
ever, the precise mechanism of the effect of the com-
bined agents remains uncertain [9]. Despite the benefit
of combination therapy, clinical trials have found
adverse events associated with LABA used as monother-
apy, leading the US FDA to institute “boxed warnings” * Correspondence: Erik.Riesenfeld@uvm.edu
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plicated by the results of a recent clinical trial suggesting
that regular treatment with short acting bronchodilators
might also be detrimental, even when used in combina-
tion with ICS [13].
The multiplicity of sites of action that ICS have in the
inflammatory cascade explains why they are currently
the most efficacious therapy for asthma [7,14]. However,
it has been suggested that LABAs also have anti-inflam-
matory properties [9,15-17] in addition to being able to
relax airway smooth muscle. With this combination of
benefits, the finding that LABA use is associated with
adverse outcomes would seem to be puzzling. On the
other hand, studies of the anti-inflammatory properties
of LABA have so far focused primarily on epithelial per-
meability and cellular accumulation in the lungs [17].
This is a limited spectrum of action compared to that
attributed to ICS. It is therefore possible that the detri-
mental consequences of LABA use arise because other
aspects of the inflammatory response are increased such
as airway wall thickening and mucus hyper-secretion.
Accordingly, we hypothesized that LABA treatment
would upregulate components of the inflammatory or
“remodelling” response that exacerbate airway closure,
and that this is prevented by concomitant use of ICS.
To address this hypothesis, we focused on how airway
hyperresponsiveness in allergically inflamed mice is
modulated by treatment with an inhaled LABA (salme-
terol), or ICS (fluticasone), or the combination of the
two. We related these physiological outcomes to mea-
sures of airway and parenchymal remodeling based on
histological indices and micro-CT imaging.
Methods
Experiments were approved by the Institutional Animal
Care and Use Committee of the University of Vermont.
Animals and the OVA Allergic Airways Disease model
Female BALB/c mice (age 6-12 weeks with n = 6-8 per
group from Jackson Laboratories, Bar Harbor, ME) were
sensitized to ovalbumin (OVA) (Sigma-Aldrich St.
Louis, MO) with alum adjuvant (aluminum hydroxide)
(Pierce Chemical, Rockford, IL) as previously described
[18]. The experimental study design scheme is shown in
Figure 1. Because of technical limitations imposed by
the protocol for computed tomography (CT) imaging,
half of each group were subjected to CT imaging
whereas the other half had BAL and histology per-
formed. Mice received intraperitoneal OVA and alum
(days 0 and 14) followed by nebulized 1% OVA in sterile
phosphate buffered saline on days 21-26 (O group). A
naïve (N) group served as a control. Nebulized treat-
ments were given for 30 minutes in a compartmenta-
lized exposure chamber using an attached Pari LC plus®
nebulizer with a Proneb® Ultra II (PARI Innovative
Manufacturers, Inc Midlothian, VA).
Drug Treatments
The O group was sub-divided to receive the following
nebulized treatments; vehicle control (V) (D-PBS/0.17%
tween 80), fluticasone (F) (6 mg/ml), salmeterol (S) (3
mg/ml) or the combination of salmeterol (3 mg/ml) and
fluticasone (FS) (6 mg/ml) (GlaxoSmithKline Middlesex,
UK). Drugs were administered once a day for 20 minutes
using the same nebulizer arrangement described above in
Figure 1 Experimental Study Design Scheme. BALB/c mice were immunized intraperitoneally with 20 micrograms of Ovalbumin (OVA) on
days 0 and 14. OVA was then nebulized daily as a challenge on days 21 to 26. Different groups of mice were treated with 20 minute
nebulizations of vehicle, fluticasone 6,000 micrograms per ml, salmeterol 3,000 micrograms per ml, or the combination of fluticasone and
salmeterol. These were dosed once daily from days 19 to 27 (9 doses).
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lected on day 28 (24 hours after the last dose).
Lung Mechanics
Mice were anesthetized with pentobarbital (90 mg/kg),
tracheostomized and ventilated with room air at a rate
of 200 breaths per minute with a tidal volume of 0.25
ml and positive end expiratory pressure of 3 cm H2O
(flexiVent, Scireq, Montreal). Mice received 2 sighs lim-
ited to a pressure of 25 cm H2O. Following this, two
baseline measurements of respiratory input impedance
(Zrs) were made followed by nebulized methacholine
challenges (saline control and methacholine at 3.125,
12.5, and 50 mg/ml). Methacholine was nebulized for 40
seconds with the inspiratory line of the ventilator con-
nected through a nebulizer (Beetle-Neb Ultrasonic
Nebulizer Drive Medical Design and Manufacturing
Port Washington, NY) using a tidal volume of 0.8 ml
with a rate adjusted to provide the same minute ventila-
tion as the baseline ventilation.
Newtonian Resistance (RN), tissue resistance or damp-
ing (G), and elastance (H) were calculated by fitting the
constant-phase model to respiratory impedance as
described previously [19-22]. Mice were then euthanized
followed by either a CT scan or a bronchoalveolar
lavage (BAL) [4,23].
Histology
Bronchoalveolar lavage (BAL) cell counts were recorded as
previously described [24]. Lungs were inflation fixed with
10% formalin at 30 cm pressure and stained with Hema-
toxylin and Eosin (H+E), Sirius red (for collagen) [25], or
fluorescent periodic acid Schiff (PAFS) to evaluate mucus
containing cells as per Evans et al. [26]. PAFS staining was
used due to its greater specificity with less background
staining than the standard PAS stain. Immersion fixation
was done with additional mice (2 from O and 2 from FS)
so that the luminal space could be visualized without dis-
ruption caused by lavage or inflation.
Morphometry
Semi-quantitative assessment of inflammation, collagen
deposition and epithelial damage was performed by
three masked readers. Epithelial thickness, collagen, and
mucin containing cells were quantified using customized
Image J software (see online supplement for a detailed
description) [27]. Slides were viewed (Zeiss, Axioskop 2
plus, Göttingen, Germany) at 10 × or 20 ×. Scoring for
inflammation and epithelial damage used a four point
scale (0-least to 3-most). The epithelial damage score
incorporated epithelial cell thickness and cell disruption.
Collagen was determined quantitatively and semi-quan-
titatively from polarized Siri u sR e ds t a i n e ds l i d e s( s e e
additional file 1 for details). PAFS positive cells were
recorded as a number of cells per micron of basement
membrane. Epithelial thickness was measured as the
area between the luminal cell membrane and the base-
ment membrane (BM) divided by the BM length in
microns.
Computed Tomography
After euthanasia, mice the mouse trachea was tied off at
3c mH 2O and imaged at 80 kV and 450 mA for 80 min
using a micro-CT scanner (eXplore, GE Medical sys-
tems) [4]. Images were converted into iso-surface ren-
derings for visualization of the air-tissue interface.
Thoracic gas volume (VTG) was determined by summing
the fractions of air in each pixel as previously described
by Lundblad et al. [4].
Statistics
Statistics were calculated using Origin 7.5 (OriginLab
Corp, Northampton, MA). ANOVA followed by Tukey-
Kramer pairwise comparisons were used to compare
treatment effects. Lung mechanics parameters were
compared using a two way ANOVA followed by a
means comparison using a Tukey test. Data are
expressed as mean ± SE. Significance was taken as p <
0.05.
Results
Bronchoalveolar Lavage
The BAL cellularity was greater in the O and V and S
groups compared to N, F and FS. Variability in the cell
counts limited the statistical significance with the con-
servative statistical test of an ANOVA with Tukey’s
Multiple Comparison Test (see Figure 2) (p < 0.01 for
ANOVA). The greatest cellularity was seen in the S
group but significance was noted only for S compared
to N, F and FS for total cells. Cell counts were at naüve
levels in both the F and FS treated groups. BALF fluid
return ranged from 0.6-0.9 ml per mouse.
Histology
Figure 3 presents representative photomicrographs from
each group. These images have pathology scores similar
to their respective group means shown in Figure 4. Sen-
sitization and challenge with O caused a significant
increase in peribronchial inflammation in the O group
compared to the N group. Fluticasone, either alone (F)
or in combination with salmeterol (FS), dramatically
reduced peribronchial inflammation to N group levels
(see Figure 3, panels D and E). There was no evidence
of reduced inflammation in the S group in which mucus
frequently adhered to the airway wall as depicted in
Figure 3, panel C. In comparing the scores of the three
readers for inflammation, an Intraclass Correlation
Coefficient (ICC) was calculated to be 0.861. P values
Riesenfeld et al. Respiratory Research 2010, 11:22
http://respiratory-research.com/content/11/1/22
Page 3 of 11for Pearson correlations were all < 0.0017. Mucus plug
formation and abundant peribronchial inflammation
were seen in the OVA treated lungs that were immer-
sion fixed (see Figure 3 panel F).
Scores of epithelial injury and thickness are also
shown in Figure 4. OVA caused an increase in epithelial
thickening that was reduced to naive levels with nebu-
lized fluticasone. Epithelial damage and thickening were
greatest in the O, V and S groups. The thickness of the
epithelium was less variable than the global pathology
score, and there was no difference attributable to airway
size in either endpoint (data not shown).
There was no significant change in peribronchial air-
way collagen deposition assessed by Sirius red staining
at the 28 day time point (data not shown).
Physiology
Baseline lung mechanics parameters (RN, G,a n dH)
were essentially equivalent between the treatment
groups (see Additional File 2, Figure S2). Overall, the
biggest differences between the treatment groups
occurred in H (Elastance) (see Figure 5). The S group
had the greatest change in H with a 6-7 fold increase
above baseline, with the next biggest response occurring
in the V group. Moreover, in both these groups the con-
stant-phase model of lung mechanics was frequently
unable to provide a satisfactory fit to impedance at the
highest methacholine doses (see Additional File 2, Fig-
ure S3). Mice in the N, F and FS groups all had similar
responses to methacholine. Salmeterol treatment alone
caused a significant increase in G (tissue resistance or
damping). There was no significant different in RN
between any of the groups at any methacholine dose.
Mice treated with fluticasone and salmeterol together
(FS) generally demonstrated the lowest level of airways
hyperresponsiveness in inflamed mice compared to
those treated with either salmeterol or fluticasone alone.
Computed Tomography
Micro-CT images revealed probable atelectasis in distal
lung regions in OVA treated mice (See Additional File
2, Figure S4). These findings were not completely elimi-
nated by any of the treatments. Lung volume measured
as the thoracic gas volume calculated from the CT
(VTG)w a sn o ts i g n i f i c a n t l yd i f f e r e n ta m o n ga n yo ft h e
groups (data not shown).
Mucin
The number of airway epithelial cells containing airway
mucin was greatest in the V and S groups and was sig-
nificantly less in the F and FS groups (Figures 6 and 7).
There was a trend for increased PAFS positive cells in
Figure 2 BALF Cell Counts. Total cells (Total), macrophages (MAC), eosinophils (EOS), neutrophils (PMN), and lymphocytes (LYM). Treatment
groups; Naïve mice (N), Inhaled OVA (6 doses) (O), OVA with vehicle control (V), salmeterol (S), fluticasone (F), and the combination (fluticasone
and salmeterol) (FS). Mean cells per ml of BAL fluid ± SE. * in Total cells p < 0.05 for S compared to. N, FS, and F. † in Total cells p < 0.05 for N,
F and FS compared to S. * in MAC p < 0.05 for S compared to V and FS. † in MAC p < 0.05 for V and FS compared to S.
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Page 4 of 11Figure 3 Histology. Representative* Hematoxylin and Eosin stained tissue sections taken with 10× objective. A) Naïve, B) OVA, C) Salmeterol
(arrow indicates mucus adherent to wall), D) Fluticasone, E) Fluticasone and Salmeterol, F) immersion fixed lung from OVA challenged mouse
demonstrating airway obstruction with mucus in bronchial lumen. *Representative figures were chosen using criteria described in the text.
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thickening and injury. A) Semi-quantitative score for peribronchial
inflammation. B) Semi-quantitative score for global epithelial
damage. C) Quantitative epithelial thickness. Groups; naïve mice (N),
OVA (O), and O mice with vehicle control (V), salmeterol (S),
fluticasone (F), and a combination of fluticasone and salmeterol (FS).
N = 4-6 mice in each group with 4 airways per mouse (averaged
for each mouse/slide). Results expressed as mean ± SE. * p < 0.05.
Figure 5 Lung Mechanics. Mechanics parameters following
nebulized saline and increasing concentrations of methacholine
(peak response as percent of baseline). Groups; naïve mice (N) (n =
7) and OVA mice treated with vehicle (V) (n = 6), salmeterol (S) (n =
7), fluticasone (F) (n = 8), salmeterol and fluticasone (FS) (n = 8). R =
RN = Newtonian resistance, G = tissue damping, H = tissue
elastance. Results expressed as mean ± SE Panel with R: NS no
significant differences between the groups. Panel with G: * p < 0.05
for S compared to V, N, F, or FS. Panel with H: * p < 0.05 for S
compared to V (p is also < 0.05 for S compared to N, F, or FS). † p
< 0.05 for S or V compared to N, F, or FS. All comparisons in this
figure are by a two way ANOVA followed by Tukey pairwise
comparisons.
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Page 6 of 11Figure 6 Mucus Staining. Representative* PAFS stained tissue sections imaged with a dual excitation filter (FITC/Texas Red) and the 20×
objective (F imaged at 10×.). A) naïve, B) OVA, C) Salmeterol, D) Fluticasone, E) Fluticasone and Salmeterol, F) immersion fixed lung from OVA
mouse demonstrating airway obstruction with mucus. *Representative figures were chosen using criteria described in the text.
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not reach statistical significance.
Discussion
The goal of the present study was to elucidate if, and to
what extent, ICS and LABA, both separately and in
combination, alter the pathophysiology of allergic
asthma. We found that fluticasone by itself, as might be
expected, completely reversed the inflammatory changes
assessed both by bronchoalveolar lavage and histologic
sections (Figures 2, 3, and 4). Alternatively, treatment
given throughout the antigen challenge phase such as
ICS may prevent the inflammatory changes from being
initiated by having a direct effect on the lung (e.g. innate
immunity). In either case, lung remodeling, particularly
in terms of mucus metaplasia and epithelial thickening,
was essentially abrogated (Figures 4, 6, and 7) and corre-
spondingly, methacholine responsiveness was returned
to (or remained at) baseline levels (Figure 5). These
findings are in keeping with the well established efficacy
of ICS that results from their broad anti-inflammatory
activity and that makes ICS the treatment of choice for
asthma [7,28].
In stark contrast to the beneficial effects of ICS, treat-
ment with the LABA salmeterol alone increased hyper-
responsiveness (Figure 5) assessed at a time point when
bronchodilation should be minimal since the measure-
ments were made 24 hours after the last dose of salme-
terol and the baseline resistance is not significantly
different (Additional File 2, Figure S2). The S group
exhibited significantly more total cells than the naive
controls and mice treated with fluticasone (Figure 2).
While there are statistically insignificant increases in
inflammation (Figure 2), epithelial damage (Figure 4), or
mucus production (Figure 7), we think that an increase
in mucus containing cells or mucus within the airway,
in combination with epithelial injury or increased
inflammation too subtle to be quantified by simple his-
tological measurements could explain the physiological
findings. Alternatively, LABA treatment might have a
more direct effect on mucin containing cells that is
independent of any effects on the inflammatory
response. We base these conclusions on a number of
interrelated findings and deductions. First, using compu-
tational modeling, we havep r e v i o u s l ys h o w nt h a t
increased airways hyperresponsiveness can be explained
by increased epithelial thickening and airway closure [6].
Mucus metaplasia would be expected to enhance airway
closure and the S group tended to show increased
mucus cell numbers. Consistent with this is the putative
role of mucus plugging in fatal human asthma cases [3].
Second, while the trend towards an increase in mucus
containing cells within the airway did not reach statisti-
cal significance, it is important to point out that the dis-
tribution of airway closure is decidedly not uniform [4].
Histological measurements that were done are averaged
through the lung and would be expected to lack the
sensitivity to detect the changes that are clearly ampli-
fied in physiological measurements. Third, the concept
that beta agonists may upregulate mucus is supported
by previous work implicating beta agonists in mucus
production in rats [29], as well as in airway epithelial
cell proliferation and airway wall thickening or injury
[ 3 0 ] .F o u r t hw eh a v es h o w e dt hat hyperresponsiveness
in elastance (H), a measure of airway closure to metha-
choline challenge is extremely sensitive to small
increases in epithelial thickness and/or airway secretions
through the formation of liquid bridges that occlude the
lumen of small airways [4,6,21,31,32]. This is supported
in the present study by CT imaging that is consistent
with airway collapse in the S group. Finally, we found
that the constant-phase model frequently did not fit
measurements of impedance very well in this particular
treatment group, consistent with instability of airway
patency and airway closure (See Additional File 2, Figure
S3) [21]. Thus, taken together the increased AHR mani-
fested in the parameter H suggests that augmentation in
AHR by S is due to enhanced airway closure likely the
result of mucus metaplasia and/or epithelial changes.
The current study supports the hypothesis that
extended therapy with LABA monotherapy worsens air-
ways hyperresponsiveness, possibly by upregulating either
aspects of the inflammatory response or mucin contain-
ing cells and exacerbating distal airway closure thus, pro-
viding a potential explanation for the rare severe adverse
events associated with LABA mono-therapy in asthmatic
Figure 7 Mucus Quantification. Mucus containing (PAFS positive)
cells. Groups include naïve mice (N) and OVA sensitized and
challenged mice treated with vehicle control (V), salmeterol (S),
fluticasone (F), and a combination of fluticasone and salmeterol (FS).
Results are expressed as means ± SE. N = 4 mice with 4 airways
averaged per mouse (slide). ANOVA p < 0.0001. * p < 0.05.
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the use of beta agonists more than a decade ago [33],
and there have been scattered reports that beta ago-
nists can increase secretory cell numbers in human air-
ways [34]. Also, airway closure has been demonstrated
to be an important feature in human asthma [35]. It is
therefore possible that peripheral airway closure played
a role in the LABA-related deaths. Of course, one
could argue that the acutely inflamed mice utilized in
t h ep r e s e n ts t u d yh a v el i m i t e dr e l e v a n c et ot h ec h r o n i c
disease of human adult asthma. On the other hand, the
FDA recently brought attention to the possible adverse
consequences of salmeterol use in the pediatric popula-
tion [36] which our acute antigen-challenged mouse
model may more closely reflect. Although the result of
the present study seems to fit with corresponding
observations in human asthmatics, they must be viewed
in the light of certain limitations. Foremost among
these is the fact that mice have important physiological
and pharmacologic differences to humans, and that
the model of allergic asthma we used reflects simply
the acute inflammatory response to a single foreign
protein. There may also be differences in the delivery
of drugs by nebulization compared with dosing a
powdered formulation. Initial titration studies with flu-
ticasone demonstrated evidence of dose dependant
anti-inflammatory effects of fluticasone suggesting ade-
quate delivery. We used this model because it has a
number of practical advantages, has been well charac-
terized, and exhibits at least some of the features
thought to be central to human asthma [6]. And while
there are a wide variety of other inflammatory animal
models or investigative techniques that exist [37], each
of these approaches has its limitations and advantages.
The most important finding of the present study is
that the adverse physiological consequences and likely,
any related inflammatory or early remodeling changes
attributable to salmeterol seem to be completely avoided
if LABA is administered in conjunction with fluticasone
(Figures 2, 2, 3, 4, 5, 6, 7). This finding is consistent
with a recent meta analysis of human clinical data show-
ing the deleterious effects of LABA appear to be abro-
gated by concomitant use of ICS [38]. Indeed, the
combination therapy used in our study was at least as
effective as fluticasone alone, and may even have been
slightly better when all of the outcomes are taken
together. Even so, the anti-inflammatory role of salme-
terol remains controversial [15,16,39]. The principal
rationale for combination therapies in asthma remains
the notion that ICS allow for the benefits of LABAs
while at the same time mitigating their disadvantages. In
other words, combining these two drugs produces an
effect that is not simply the sum of their individual
effects. Exactly why synergy should exist between ICS
and LABA is not entirely clear. One possibility is beta
agonists directly activate the glucocorticoid receptor
[9,40]. Alternatively, we have recently demonstrated
synergistic interactions between the peripheral remodel-
ing of allergic inflammation and enhanced central air-
w a yn a r r o w i n gi nm i c e[ 2 1 ] .T h u s ,t h e r ei sm o r et h a n
one reason why a combination therapy would be super-
ior as one agent treats inflammation and the other treats
abnormal smooth muscle function and may involve pre-
viously underappreciated mechanisms.
Structural remodeling has long been linked to asthma
and this topic has been heavily reviewed [1]. What is
unclear is what portion of these structural changes lead to
the greatest changes in lung function. Fibrotic changes tra-
ditionally considered targets for therapy may in fact; serve a
protective role in reducing AHR [2,25]. On the other hand,
early changes such as those seen in this model including
epithelial thickening and mucus production may produce a
more significant decrement in lung function and hyperre-
sponsiveness representing the physiologically important
early elements of the remodeling process [41-43]. Several
potential therapies impact mucus metaplasia including the
MARCKS related peptide that can reduce mucus release
into airways [44,45]. Cysteinyl leukotrienes receptor antago-
nists have been shown to reduce mucus plugging, smooth
muscle hyperplasia, and subepithelial fibrosis [46]. Surpris-
ingly, beta blockers have also been shown to reduce mucin
content [47]. Taken together with our findings it is reason-
able to suggest that airway mucus metaplasia might be a
promising therapeutic target in asthma, particularly in
patients who are resistant to steroids [28].
Conclusions
We have investigated the effects of fluticasone and sal-
meterol, both separately and in combination, on lung
structure and function in allergically inflamed mice. Sal-
meterol alone worsened airways hyperresponsiveness
and increased (or failed to reduce) histologic markers of
inflammation, remodeling and mucus hyperplasia at
least as severely as those associated with untreated
inflamed animals. The pattern of hyperresponsiveness
was consistent with increased closure of small airways.
Concomitant administration of fluticasone maintained
or reduced all biomarkers to the level of naüve animals.
These results have implications related to the treatment
of early asthma and suggest that treatment with LABA
alone is detrimental, but that any adverse effects are
ameliorated with the combined use of ICS, in support of
current clinical practice.
Abbreviations used
AHR: airways hyperresponsiveness; BALF: bronchoalveolar
lavage fluid; BM: basement membrane; COD: coefficient of
determination; F: fluticasone; FS: combination of
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elastance; ICS: inhaled corticosteroid; LABA: long acting
bronchodilator; O: OVA (ovalbumin); Rn: Newtonian
Resistance; S: salmeterol; SABA: short acting bronchodila-
tor; V: Vehicle control in addition to OVA; VTG: Thoracic
gas volume (lung volume calculated from the CT).
Additional file 1: Supplemental morphometry methods. This file
contains additional technical information for the morphometry
techniques used. Figure S1: This illustrates the quantitative collagen
measurement technique using image J software.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1465-9921-11-
22-S1.DOC]
Additional file 2: Additional Data including baseline mechanics, z
values and CT images: Figure S2: Baseline lung mechanics parameters
(Supplemental Figure 2.doc) Figure S3. Number of z values with a
coefficient of determination (COD) less than 0.8. Figure S4:
Representative CT images.
Click here for file
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